Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement

STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement confirmed by

Johnson & Johnson Says 50% Of Patients Progression-Free At Five Years After Single Carvykti Infusion In Phase 2 Multiple Myeloma Trial

8 Of 11 Sectors Fall In Thursday Trading As Leaders Split

Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than